1. Home
  2. OBE vs ALLO Comparison

OBE vs ALLO Comparison

Compare OBE & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Obsidian Energy Ltd.

OBE

Obsidian Energy Ltd.

HOLD

Current Price

$9.74

Market Cap

526.9M

Sector

Energy

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$2.60

Market Cap

539.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OBE
ALLO
Founded
1979
2017
Country
Canada
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
526.9M
539.4M
IPO Year
2005
2018

Fundamental Metrics

Financial Performance
Metric
OBE
ALLO
Price
$9.74
$2.60
Analyst Decision
Hold
Buy
Analyst Count
1
11
Target Price
$10.00
$8.40
AVG Volume (30 Days)
907.9K
4.6M
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
34.09
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$20.21
$144,130.60
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.88
$0.86
52 Week High
$9.81
$2.80

Technical Indicators

Market Signals
Indicator
OBE
ALLO
Relative Strength Index (RSI) 70.50 57.21
Support Level $5.57 $2.14
Resistance Level N/A $2.71
Average True Range (ATR) 0.40 0.22
MACD 0.02 0.01
Stochastic Oscillator 98.34 80.31

Price Performance

Historical Comparison
OBE
ALLO

About OBE Obsidian Energy Ltd.

Obsidian Energy Ltd is an intermediate-sized oil and gas producer with strategic assets in Alberta. It operates in a single reporting segment that is exploration, development, and holding an interest in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin. The company generates the majority of the revenue from the Sale of Oil.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: